Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Europe Commercial | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,755 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Sale · Disposed 30,000 · Balance 55,755 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2021 Filed Mar 8, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-018508 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017755 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 993 | $10.88 | $10,803.44 |
DisclosureSEC source: 0001209191-21-017755 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,873 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.840 to $10.915, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017755 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,598 | $10.85 | $223,506.84 |
DisclosureSEC source: 0001209191-21-015822 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.775 to $11.005, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015822 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,795 Underlying: Ordinary Shares · 20,598 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-015822 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009627 · doc4.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,135 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9,2022. F7 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9,2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 55,287 | $12.72 | $703,300.40 |
DisclosureSEC source: 0001209191-21-009627 · doc4.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 13,135 | $12.72 | $167,089.02 |
DisclosureSEC source: 0001209191-21-009627 · doc4.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,052 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantOrdinary Shares | 55,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009627 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,187 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units. F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-009627 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 13:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049921 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F6 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 13:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 333 | $8.98 | $2,991.81 |
DisclosureSEC source: 0001209191-20-049921 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9800 to $8.9850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 13:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 698 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-049921 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020161 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F6 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 616 | $7.17 | $4,417.58 |
DisclosureSEC source: 0001209191-20-020161 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.2000, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 11:31 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-020161 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016458 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,101 Underlying: Ordinary Shares · 2,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 991 | $11.77 | $11,659.81 |
DisclosureSEC source: 0001209191-20-016458 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,719 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7300 to $11.8100, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 13:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016458 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 12:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 82,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014846 · doc4.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,393 Underlying: Ordinary Shares · 82,393 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 20,598 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 20,599 vesting on February 28, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 11:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,199 | $12.24 | $75,886.30 |
DisclosureSEC source: 0001209191-20-008161 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,612 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2400 to $12.2450, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008161 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,270 Underlying: Ordinary Shares · 13,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9,2022. F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9,2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2020 Filed Feb 11, 2020 11:52 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008161 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050261 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,488 vesting on September 18, 2018 and 2,489 vesting on September 18, 2019. F5 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,488 vesting on September 18, 2018 and 2,489 vesting on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,176 | $7.82 | $9,196.67 |
DisclosureSEC source: 0001209191-19-050261 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,676 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $7.84, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 11:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-050261 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 10:58 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 696 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049108 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698 Underlying: Ordinary Shares · 696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F4 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 10:58 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 333 | $7.16 | $2,384.28 |
DisclosureSEC source: 0001209191-19-049108 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| September 09, 2019 Filed Sep 11, 2019 10:58 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049108 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 12:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,297 | $16.64 | $21,588.05 |
DisclosureSEC source: 0001209191-19-020161 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.6400 to $16.6516, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020161 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297 Underlying: Ordinary Shares · 1,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2019 Filed Mar 19, 2019 12:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-020161 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 16.6400 to $16.6516, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-019324 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 714 vesting on March 12, 2018 and 715 vesting on March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 714 vesting on March 12, 2018 and 715 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 715 | $15.69 | $11,218.21 |
DisclosureSEC source: 0001209191-19-019324 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.670 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 11:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-019324 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,098 | $16.88 | $35,423.47 |
DisclosureSEC source: 0001209191-19-016081 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.1316, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 47,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017227 · doc4.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,761 Underlying: Ordinary Shares · 47,761 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016081 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,199 Underlying: Ordinary Shares · 2,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F4 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2019 Filed Mar 5, 2019 12:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-016081 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051770 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489 Underlying: Ordinary Shares · 2,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 18, 2017, with 2,488 vesting on September 18, 2018 and 2,489 vesting on September 18, 2019. F4 · derivative.expiration_date: Restricted share units were granted on September 18, 2017, with 2,488 vesting on September 18, 2018 and 2,489 vesting on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 2,488 | $23.69 | $58,943.21 |
DisclosureSEC source: 0001209191-18-051770 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.680 to $23.720, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-051770 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 696 | $21.25 | $14,790.14 |
DisclosureSEC source: 0001209191-18-050469 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.2500 to $21.2515, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 09, 2018 Filed Sep 11, 2018 20:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 696 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050469 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,394 Underlying: Ordinary Shares · 696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F4 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 696 vesting on each of September 9, 2018 and September 9, 2019 and 698 vesting on September 9, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 09, 2018 Filed Sep 11, 2018 20:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-050469 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,297 | $17.89 | $23,205.92 |
DisclosureSEC source: 0001209191-18-020857 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.87 to $17.92, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020857 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,594 Underlying: Ordinary Shares · 1,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F4 · derivative.expiration_date: Restricted share units were granted on March 17, 2016, with 1,297 vesting on each of March 17, 2018, March 17, 2019 and March 17, 2020. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 17, 2018 Filed Mar 20, 2018 20:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-020857 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.